Report: Screening programs in Italy (Italy): Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{forpolicymakers}} | {{forpolicymakers}} | ||
Go back to [[Italy]] page | Go back to [[Italy]] page | ||
'''Primary purpose:''' Assesses annual cancer screening programs in Italy, indicating substantial participation in mammography and cervical screenings, significant progress in colorectal screening, and disparities in coverage between regions. | '''Primary purpose:''' Assesses annual cancer screening programs in Italy, indicating substantial participation in mammography and cervical screenings, significant progress in colorectal screening, and disparities in coverage between regions. | ||
''' | '''Sponsor, manager or home institution:''' [[dataOwner::Osservatorio Nazionale Screening]]; [[dataOwner::Ministero della Salute]]. | ||
''' | '''Type of information:''' Effective extent of mammography, cervical and colorectal [[availableVariable::screening]]; Participation (%) in screenings according to the [[availableVariable::region|country]] of origin; Waiting times; Invitations; Availability of pre-operative [[availableVariable::diagnosis]]; [[availableVariable::medical procedures|Conservative surgery]]; Total number of persons invited; Number of persons participating in the invitation; Acceptance of the invitation; Number of persons examined in the period; Proportion of persons recalled for further investigation; Benign biopsies; Cancer identification rate; Invasive cancer identification rate; Percentage of conservative surgical treatment in invasive tumors; Mammography performed within the last 2 years; Fecal occult blood test programs - Main results in the two-[[availableVariable::year]] period; Programs with Rectosigmoidoscopy; Examination for the prevention of colorectal cancer in the recommended times (%) persons; Lesions with CIN2+ histology identified; Introduction of the human papilloma virus (Hpv) test as a screening test; Preventive test coverage in the last 3 years. | ||
''' | '''Data level:''' [[dataLevel::national level]] and [[dataLevel::regional level]]. | ||
''' | '''Cancer areas of interest:''' [[hasCancerType::C15-C26: Digestive system cancers]], [[hasCancerType::C50: Breast cancer]] and [[hasCancerType::C51-C58: Female genitalia cancer]]. [https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2305 Click here to learn more]. | ||
'''Access to information:''' [https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2305 Click here to access]. | '''Access to information:''' [https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2305 Click here to access]. | ||
Revision as of 17:59, 16 July 2024
Go back to Italy page
Primary purpose: Assesses annual cancer screening programs in Italy, indicating substantial participation in mammography and cervical screenings, significant progress in colorectal screening, and disparities in coverage between regions.
Sponsor, manager or home institution: Osservatorio Nazionale Screening; Ministero della Salute.
Type of information: Effective extent of mammography, cervical and colorectal screening; Participation (%) in screenings according to the country of origin; Waiting times; Invitations; Availability of pre-operative diagnosis; Conservative surgery; Total number of persons invited; Number of persons participating in the invitation; Acceptance of the invitation; Number of persons examined in the period; Proportion of persons recalled for further investigation; Benign biopsies; Cancer identification rate; Invasive cancer identification rate; Percentage of conservative surgical treatment in invasive tumors; Mammography performed within the last 2 years; Fecal occult blood test programs - Main results in the two-year period; Programs with Rectosigmoidoscopy; Examination for the prevention of colorectal cancer in the recommended times (%) persons; Lesions with CIN2+ histology identified; Introduction of the human papilloma virus (Hpv) test as a screening test; Preventive test coverage in the last 3 years.
Data level: national level and regional level.
Cancer areas of interest: C15-C26: Digestive system cancers, C50: Breast cancer and C51-C58: Female genitalia cancer. Click here to learn more.
Access to information: Click here to access.